Clinical Guest Contributors

1. The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option 8/28/2026

   Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.

2. Planning A Global Clinical Trial With The Right Sites, Not The Most Sites 8/27/2026

   Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.

3. Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections 8/27/2026

   Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

4. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

   Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

5. Turning A Historically Limited Modality Into A Respiratory Drug Opportunity 8/26/2026

   How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.

6. Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy 8/25/2026

   Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

7. Accountability Gaps Can Break Clinical Supply Contracts 8/24/2026

   Contract gaps can create clinical supply failures when responsibilities differ across agreements. See how aligning obligations can prevent costly disputes, delays, and risks.

8. 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations 8/24/2026

   Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

9. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

   BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

10. Sustainable Patient Engagement: Your Enrollment And Representation Depend On It 8/21/2026

    Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.